Hirotsugu Yamada Selected Research

Scarlet Red (Sudan IV)

6/2021	Inhibition of S1P Receptor 2 Attenuates Endothelial Dysfunction and Inhibits Atherogenesis in Apolipoprotein E-Deficient Mice.
11/2019	Vildagliptin, a DPP-4 Inhibitor, Attenuates Endothelial Dysfunction and Atherogenesis in Nondiabetic Apolipoprotein E-Deficient Mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hirotsugu Yamada Research Topics

Disease

18	Atherosclerosis 11/2021 - 09/2010
12	Hypertension (High Blood Pressure) 12/2019 - 10/2004
11	Inflammation (Inflammations) 11/2021 - 02/2010
10	Type 2 Diabetes Mellitus (MODY) 01/2021 - 08/2015
9	Heart Failure 01/2021 - 11/2004
8	Coronary Artery Disease (Coronary Atherosclerosis) 01/2021 - 12/2014
8	Cardiovascular Diseases (Cardiovascular Disease) 01/2020 - 06/2013
7	Atherosclerotic Plaque (Atheroma) 11/2019 - 09/2011
5	Atrial Fibrillation 01/2022 - 06/2003
5	Neoplasms (Cancer) 11/2021 - 01/2017
4	Body Weight (Weight, Body) 12/2021 - 02/2010
4	Dyslipidemias (Dyslipidemia) 01/2021 - 12/2014
4	Thrombosis (Thrombus) 07/2020 - 12/2011
4	Carotid Artery Diseases 01/2020 - 09/2010
4	Myocardial Infarction 01/2019 - 03/2002
3	Hyperuricemia 01/2022 - 06/2016
3	Diabetes Mellitus 01/2021 - 12/2014
3	Fibrosis (Cirrhosis) 01/2021 - 07/2015
3	Insulin Resistance 01/2021 - 02/2010
3	Acute Coronary Syndrome 03/2019 - 10/2015
3	Ischemia 01/2018 - 01/2013
3	Essential Hypertension 01/2015 - 10/2004
3	Myocardial Ischemia (Ischemic Heart Diseases) 11/2013 - 11/2007
3	Myocarditis (Carditis) 01/2013 - 02/2011
2	Venous Thromboembolism 07/2022 - 01/2018
2	Cardiac Arrhythmias (Arrythmia) 01/2021 - 01/2017
2	Left Ventricular Dysfunction 01/2021 - 02/2011
2	Cardiomyopathies (Cardiomyopathy) 12/2019 - 01/2018
2	Infections 01/2018 - 02/2011
2	Spasm (Spasms) 01/2018 - 10/2017
2	Arteriosclerosis 01/2016 - 01/2015
2	Hypotension (Low Blood Pressure) 08/2015 - 12/2006
2	Sarcoidosis (Schaumann Disease) 06/2015 - 01/2011
2	Edema (Dropsy) 01/2014 - 01/2013
2	Ventricular Tachycardia 11/2013 - 01/2011
2	Pathologic Constriction (Stenosis) 06/2013 - 06/2003

Drug/Important Bio-Agent (IBA)

9	Biomarkers (Surrogate Marker)IBA 01/2021 - 02/2011
8	Apolipoproteins E (ApoE)IBA 11/2021 - 10/2015
8	LipidsIBA 11/2021 - 07/2015
7	ApolipoproteinsIBA 11/2021 - 11/2016
7	Eicosapentaenoic AcidIBA 03/2019 - 12/2014
7	Docosahexaenoic AcidsIBA 03/2019 - 12/2014
5	AnticoagulantsIBA 07/2022 - 06/2013
4	Angiotensin IIIBA 01/2021 - 12/2006
4	Factor Xa (Coagulation Factor Xa)IBA 01/2021 - 10/2015
4	Hypoglycemic Agents (Hypoglycemics)IBA 01/2020 - 01/2016
3	RivaroxabanIBA 07/2022 - 10/2015
3	Febuxostat FDA Link 01/2022 - 06/2016
3	HDL CholesterolIBA 12/2021 - 01/2015
3	CanagliflozinIBA 01/2021 - 01/2017
3	RNA (Ribonucleic Acid)IBA 05/2020 - 02/2011
3	Uric Acid (Urate)IBA 01/2020 - 01/2015
3	Dipeptidyl-Peptidase IV InhibitorsIBA 11/2019 - 08/2015
3	SodiumIBA 01/2018 - 07/2016
3	Sitagliptin Phosphate (Januvia)FDA Link 11/2017 - 01/2016
3	Dobutamine FDA LinkGeneric 10/2017 - 03/2002
3	CreatinineIBA 01/2017 - 06/2011
3	C-Reactive ProteinIBA 01/2017 - 09/2011
3	Brain Natriuretic Peptide (Natrecor)FDA Link 01/2017 - 12/2014
3	DiureticsIBA 07/2016 - 01/2011
3	Arachidonic Acid (Vitamin F)IBA 12/2015 - 12/2014
3	Proteins (Proteins, Gene)FDA Link 05/2015 - 01/2013
3	LDL CholesterolIBA 01/2015 - 02/2010
2	edoxabanIBA 07/2022 - 01/2018
2	Triglycerides (Triacylglycerol)IBA 12/2021 - 06/2011
2	DNA (Deoxyribonucleic Acid)IBA 11/2021 - 01/2019
2	InterferonsIBA 11/2021 - 05/2015
2	Scarlet Red (Sudan IV)IBA 06/2021 - 11/2019
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 03/2019 - 01/2016
2	Toll-Like Receptor 9IBA 01/2019 - 01/2018
2	CollagenIBA 10/2018 - 10/2015
2	Peptide Hydrolases (Proteases)FDA Link 10/2018 - 02/2011
2	Glucose (Dextrose)FDA LinkGeneric 01/2018 - 01/2017
2	Sodium-Glucose Transporter 2 InhibitorsIBA 01/2018 - 01/2016
2	Thrombin FDA Link 01/2018 - 02/2011
2	SymportersIBA 01/2018 - 01/2017
2	Indicators and Reagents (Reagents)IBA 01/2017 - 09/2011
2	Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA 11/2016 - 12/2014
2	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 11/2016 - 12/2014
2	Pharmaceutical PreparationsIBA 06/2016 - 01/2011
2	CytokinesIBA 01/2016 - 02/2011
2	Therapeutic UsesIBA 01/2016 - 09/2011
2	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 10/2015 - 08/2015
2	Adrenal Cortex Hormones (Corticosteroids)IBA 06/2015 - 01/2011
2	AlbuminsIBA 01/2015 - 02/2010
2	GhrelinIBA 12/2014 - 11/2013
2	Telmisartan (Micardis)FDA Link 01/2014 - 09/2011
2	oxidized low density lipoproteinIBA 01/2014 - 02/2010
2	Nitric Oxide (Nitrogen Monoxide)FDA Link 05/2013 - 02/2010
2	Epoprostenol (Prostacyclin)FDA LinkGeneric 01/2013 - 01/2012
2	ONO 1301IBA 01/2013 - 01/2012

Therapy/Procedure

13	Therapeutics 01/2021 - 12/2003
4	Stents 03/2019 - 07/2011
4	Cardiac Rehabilitation 10/2018 - 01/2014
2	Catheter Ablation 01/2022 - 01/2011
2	Percutaneous Coronary Intervention 11/2021 - 01/2015
2	Exercise Therapy (Therapy, Exercise) 01/2020 - 01/2016
2	Drug Therapy (Chemotherapy) 12/2019 - 06/2013
2	Aftercare (After-Treatment) 01/2017 - 10/2004
2	Ligation 11/2013 - 01/2006